BioNTech enters CAR-T cell therapy collaboration with Autolus
German biotech BioNTech (Nasdaq: BNTX) and USA-based Autolus Therapeutics (Nasdaq: AULT) today announced a strategic collaboration aimed at advancing both companies’ autologous CAR-T programs towards commercialization, pending regulatory authorizations.
In connection with the strategic collaboration, the companies entered into a license and option agreement and a securities purchase agreement.
BioNTech, which has generated a pile of cash due to the huge success of its Pfizer (NYSE: PFE) partnered COVID-19 vaccine Comirnaty - that is already being invested in numerous collaborations, has now agreed to purchase $200 million of Autolus’ American Depositary Shares in a private placement, and will have a right to appoint a director to the board of Autolus, whose shares were up 2.9% at $6.32 pre-market.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze